Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE 3 open-label extension of pediatric bosentan twice-daily versus three-times-daily dosing in children with pulmonary arterial hypertension
NL-OMON36321Phase 3Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Nov 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of bosentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Started Nov 2011; status: active, not recruiting.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON36321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36321.